2’-氯-3’-氟苯乙酮 | 161957-57-9

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2’-氯-3’-氟苯乙酮
• 中文别名: 1-(2-氯-3-氟苯基)乙酮；2-氯-3-氟苯乙酮
• 英文名称: 1-(2-chloro-3-fluorophenyl)ethanone
• CAS: 161957-57-9
• 化学式: C₈H₆ClFO
• mdl: MFCD13194221
• 分子量: 172.586
• InChiKey: YLXXXDDQBMAZKT-UHFFFAOYSA-N

物化性质

• 沸点：
  205℃
• 密度：
  1.258
• 闪点：
  78℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

反应信息

• 作为反应物：
  描述：

  2’-氯-3’-氟苯乙酮 在 titanium(IV) isopropylate 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 (S)-tert-butyl 3-(2-chloro-3-fluorophenyl)-3-((R)-1,1-dimethylethylsulfinamido) butanoate
  参考文献：
  名称：

  PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

  摘要：

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物的通用公式为I： 其中变量A4，A5，A6，A8，公式I中的R1和R2，R3和R7各自独立定义如下。本发明还提供了包含这些化合物的药物组合物，以及使用这些化合物和组合物治疗与A-β斑块形成和沉积相关的疾病和/或状况，这些疾病和/或状况是由BACE的生物活性引起的。这样的BACE介导的疾病包括，例如，阿尔茨海默病，认知缺陷，认知障碍，精神分裂症和其他中枢神经系统疾病。本发明进一步提供了公式II和III的化合物，以及其子公式的实施例，中间体和用于制备公式I-III化合物的过程和方法。

  公开号：

  US20140249104A1
• 作为产物：
  描述：

  间氟苯甲酸 在 四甲基乙二胺 、 六氯乙烷 、 甲基锂 、 仲丁基锂 作用下， 生成 2’-氯-3’-氟苯乙酮
  参考文献：
  名称：

  通过邻金属化反应合成2,3-二卤代苯甲酸和相关的苯乙酮的区域特异性合成

  摘要：

  基于简洁一般路线混合2,3- dihalobenzoic酸和相关的苯乙酮定向邻-metalation和本位脱甲硅基反应进行了描述。

  DOI：

  10.1016/0040-4039(94)02385-o

文献信息

• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• Design, Synthesis and Fungicidal Activity of 2-Substituted Phenyl-2-oxo-, 2-Hydroxy- and 2-Acyloxyethylsulfonamides
  作者：Minlong Wang、Peng Rui、Caixiu Liu、Ying Du、Peiwen Qin、Zhiqiu Qi、Mingshan Ji、Xinghai Li、Zining Cui

  DOI：10.3390/molecules22050738

  日期：——

  Sulfonyl-containing compounds, which exhibit a broad spectrum of biological activities, comprise a substantial proportion of and play a vital role, not only in medicines but also in agrochemicals. As a result increasing attention has been paid to the research and development of sulfonyl derivatives. A series of thirty-eight 2-substituted phenyl-2-oxo- III, 2-hydroxy- IV and 2-acyloxyethylsulfonamides V were

  表现出广泛生物活性的含磺酰基化合物不仅在药物中而且在农药中占很大一部分，并起着至关重要的作用。结果，已经越来越关注磺酰基衍生物的研究和开发。得到一系列38个2-取代的苯基-2-氧代-III，2-羟基-IV和2-酰氧基乙基磺酰胺V，并通过IR，1 H-NMR和元素分析证实了它们的结构。评估了对灰葡萄孢菌株DL-11和HLD-15的体外和体内生物活性，这两种菌株在对嘧啶酮的敏感性方面有所不同。体外活性结果表明，化合物V-1和V-9对敏感菌株DL-11的EC50值为0.10，0.01 mg L-1，对耐药菌株HLD-15的EC50值为3.32，7.72 mg L-1，分别。对于抗灰葡萄孢的体内活性，化合物V-13和V-14显示出比商业杀真菌剂嘧啶酮和嘧啶酮更好的防治效果。进一步的体外生物测定表明，化合物III，IV和V具有针对不同植物病原性真菌的广谱杀真菌谱。大多数标题化合物显示出较高的杀真菌活
• [EN] IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS DE DIOXYDE D'IMINOTHIADIAZINE COMME INHIBITEURS DE BACE, COMPOSITIONS ET LEUR UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011044181A1

  公开（公告）日：2011-04-14

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-,L2-, and L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些亚氨基噻二嗪二氧化物化合物，包括化合物式(I)的化合物和其立体异构体，以及所述化合物立体异构体的药学上可接受的盐，其中每个R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-都是独立选择并在此定义。该发明的新型亚氨基噻二嗪二氧化物化合物出人意料地表现出具有优势的BACE抑制剂特性和/或用于治疗和预防与β-淀粉样蛋白（Aβ）产生相关的各种病理的特性。还公开了包括一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的制药组合物，并揭示了在治疗与淀粉样β（Aβ）蛋白相关的病理，包括阿尔茨海默病中使用它们的方法。
• IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE
  申请人：Scott Jack D.

  公开号：US20120183563A1

  公开（公告）日：2012-07-19

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): (I) and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -,L 2 -, and L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (Aβ) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些亚硫酰二氮杂环化合物，包括化合物式（I）：（I）及其立体异构体和所述化合物立体异构体的药学上可接受的盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、L2-和L3-各自独立选择并如所定义。本发明的新型亚硫酰二氮杂环化合物出人意料地表现出预期的性质，使它们作为BACE抑制剂和/或用于治疗和预防与β-淀粉样蛋白（Aβ）产生相关的各种病理学具有优势。还公开了包括一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的制药组合物，以及用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
  申请人：Scott Jack D.

  公开号：US20140296221A1

  公开（公告）日：2014-10-02

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些亚氨基噻二嗪二氧化物化合物，包括化合物公式（I）的化合物：以及其立体异构体和该化合物立体异构体的药学上可接受的盐，其中每个R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-独立选择并在此定义。本发明的新型亚氨基噻二嗪二氧化物化合物出乎意料地表现出有利于作为BACE抑制剂和/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）产生相关的各种病理的性质。还公开了包括一个或多个此类化合物（单独和与一个或多个其他活性剂的组合）的制药组合物，以及用于治疗与淀粉样β（Aβ）蛋白相关的病理，包括阿尔茨海默病的制备和使用方法。